Johnson & Johnson (NYSE:JNJ) Price Target Cut to $175.00

Johnson & Johnson (NYSE:JNJ) had its target price lowered by stock analysts at Royal Bank of Canada from $181.00 to $175.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Royal Bank of Canada’s price target indicates a potential upside of 20.08% from the stock’s current price.

Several other research firms have also weighed in on JNJ. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Monday. Morgan Stanley reduced their price objective on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 24th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Finally, Raymond James lifted their price target on shares of Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $175.86.

Johnson & Johnson Stock Up 0.7 %

JNJ opened at $145.74 on Wednesday. The firm has a market cap of $351.20 billion, a price-to-earnings ratio of 9.09, a PEG ratio of 2.40 and a beta of 0.53. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.91 and a current ratio of 1.16. The firm’s 50-day simple moving average is $156.32 and its 200-day simple moving average is $155.68. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $175.97.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.64 by $0.07. The firm had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.43%. The company’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.68 earnings per share. Equities research analysts anticipate that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Insider Transactions at Johnson & Johnson

In other news, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the sale, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Institutional Trading of Johnson & Johnson

A number of institutional investors have recently bought and sold shares of the business. Plimoth Trust Co. LLC raised its position in shares of Johnson & Johnson by 4.6% in the 1st quarter. Plimoth Trust Co. LLC now owns 34,163 shares of the company’s stock valued at $5,404,000 after buying an additional 1,513 shares in the last quarter. Silverlake Wealth Management LLC increased its position in Johnson & Johnson by 1.3% during the 1st quarter. Silverlake Wealth Management LLC now owns 24,449 shares of the company’s stock worth $3,868,000 after purchasing an additional 302 shares in the last quarter. Naviter Wealth LLC increased its position in Johnson & Johnson by 43.8% in the 1st quarter. Naviter Wealth LLC now owns 20,281 shares of the company’s stock valued at $3,208,000 after acquiring an additional 6,174 shares during the period. Quattro Financial Advisors LLC increased its position in Johnson & Johnson by 27,610.8% in the 1st quarter. Quattro Financial Advisors LLC now owns 43,506 shares of the company’s stock valued at $6,882,000 after acquiring an additional 43,349 shares during the period. Finally, MV Capital Management Inc. increased its position in Johnson & Johnson by 5.3% in the 1st quarter. MV Capital Management Inc. now owns 18,942 shares of the company’s stock valued at $2,996,000 after acquiring an additional 947 shares during the period. Institutional investors own 69.55% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.